Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186

Current Eye Research

Volumn 33, Issue 7, 2008, Pages 599-609

  Falkenstein, Iryna A ^a   Cheng, Lingyun ^a   Wong Staal, Flossie ^b   Tammewar, Ajay M ^c   Barron, Erin C ^c   Silva, Gabriel A ^c   Li, Qi Xiang ^b   Yu, Dehua ^b   Hysell, Michelle ^b   Liu, Guohong ^b   Ke, Ning ^b   Macdonald, James E ^b   Freeman, William R ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Immusol Inc   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Age related macular degeneration; Anti angiogenic treatment; Anti proliferative treatment; Choroidal neovascularization; Retina

Indexed keywords

3 [1 (3 HYDROXY 4 METHOXYPHENYL)METHYLIDENE] 6 METHYLCHROMAN 4 ONE; 4',6 DIAMIDINO 2 PHENYLINDOLE; ANGIOGENESIS INHIBITOR; IMS 2186; PHOSPHATE BUFFERED SALINE; TRIAMCINOLONE ACETONIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN 3T3; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; FIBROBLAST; FLUORESCENCE ANGIOGRAPHY; HELA CELL; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; LASER; MACROPHAGE MIGRATION INHIBITION; MOUSE; NONHUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; RABBIT; RAT; RETINA MACULA AGE RELATED DEGENERATION; SLIT LAMP; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CHOROIDAL NEOVASCULARIZATION; CHROMONES; DINOPROSTONE; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; ENDOTHELIUM, VASCULAR; FIBROBLASTS; FLUORESCEIN ANGIOGRAPHY; HUMANS; MICE; NIH 3T3 CELLS; PIGMENT EPITHELIUM OF EYE; RABBITS; RATS; RATS, INBRED BN; TUMOR CELLS, CULTURED; UMBILICAL VEINS; WOUND HEALING;

EID: 46749109602     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680802226582     Document Type: Article

References (23)

1. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640-1642.
2. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.
3. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
4. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. MARINA study group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
5. Spaide RF, Laud K, Fine HF, Klancnik JM, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-390.
6. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
7. Freeman WR, Falkenstein I. Avastin and new treatments for AMD: Where are we? Retina. 2006;26:853-858.
8. Giuliano C, Jairaj M, Zafiu CM, Laufer R. Direct determination of unbound intrinsic drug clearance in the microsomal stability assay. Drug Metab Dispos. 2005;33:1319-1324.
9. Yu D, MacDonald J, Josephs S, Liu Q, Nguy V, Tor Y, Wong-Staal F, Li QX. MDDD, a 4,9-diazapyrenium derivative is selective toxic to glioma by inducing growth arrest at G0/G1 without p53. Investigational New Drugs. 2006:24:489-498.
10. Min JK, Han KY, Kim EC, Kim YM, Lee SW, Kim OH, Kim KW, Gho YS, Kwon YG. Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res. 2004;64:644-651.
11. Cheng L, Hostetler KY, Chaidhawangul S, Gardner MF, Beadle JR, Toyoguchi M, Bergeron-Lynn G, Freeman WR. Treatment of prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-o-hexadecylpropanediol-3- phospho-ganciclovir. Invest Ophthalmol Vis Sci. 2002;43:515-521.
12. Lu S, Cheng L, Hostetler KY, Koh HJ, Beadle JR, Davidson MC, Freeman WR. Intraocular properties of hexadecyloxypropyl-cycliccidofovir in Guinea pigs. J Ocul Pharmacol Ther. 2005;21:205-209.
13. Koh HJ, Bessho K, Cheng L, Bartsch DU, Jones TR, Bergeron-Lynn G, Freeman WR. Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6. Invest Ophthalmol Vis Sci. 2004;45:635-640.
14. El Bradley M, Cheng L, Bartsch DU, Appelt K, Rodanant N, Bergeron-Lynn G, Freeman WR. Preventive versus treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization. J Ocul Pharmacol Ther. 2004;20:217-236.
15. He S, Ding Y, Zhou J, Krasnoperov V, Zozulya S, Kumar SR, Ryan SJ, Gill PS, Hinton DR. Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci. 2005;46:4772-4779.
16. Silva GA, Czeisler C, Niece KL, Beniash E, Harrington DA, Kessler JA, Stupp SI. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science. 2004;303:1352-1355.
17. Ho M, Yu D, Davidson MC, Silva GA. Comparison of standard surface chemistries for culturing mesenchymal stem cells prior to neural differentiation. Biomaterials. 2006;27:4333-4339.
18. Tamura K, Sakurai T, Kogo H. Relationship between prostaglandin E2 and vascular endothelial growth factor (VEGF) in angiogenesis in human vascular endothelial cells. Vascul Pharmacol. 2006;44:411-416.
19. Geltzer A, Turalba A, Vedula SS. Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular agerelated macular degeneration. Cochrane Database Syst Rev. 2007;Oct 17(4):CD005022.
20. Kato A, Kimura H, Okabe K, Okabe J, Kunou N, Nozaki M, Ogura Y. Suppression of laser-induced choroidal neovascularization by posterior sub-tenon administration of triamcinolone acetonide.Retina. 2005;25(4):503-509.
21. Ciulla TA, Criswell MH, Danis RP, Fronheiser M, Yuan P, Cox TA, Csaky KG, Robinson MR. Choroidal neovascular membrane inhibition in a laser-treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br J Ophthalmol. 2003;87(8):1032-1037.
22. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol. 2001;119(3):399-404.
23. Lee J, Freeman WR, Azen SP, Chung EJ, Koh HJ. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: One-year results. Retina. 2007;27(9):1205-1213.